PJ34 is a potent specific inhibitor of PARPl/2 with IC50 of 110 nM and 86 nM, respectively.

A-966492 is a selective and orally bioavailable PARP [poly(ADP-ribose) polymerase] inhibitor with potential anticancer activity.

Niraparib Tosylate (also known as MK-4827; MK4827; Zejula), the tosylate salt of niraparib, is an orally bioavailable and selective inhibitor of PARP1/2 (IC50 = 3.8 nM and 2.1nM) that gained FDA approval in March 2017 for the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

AZD-2461 is a novel, selective and potent inhibitor of Poly (ADP-ribose) polymerase (PARP) with potential anticancer activity.

Niraparib HCl (MK-4827; MK4827; Zejula), the hydrochloride salt of Niraparib, is a PARP1/2 inhibitor that has been approved by for for the maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

AG14361 (AG-14361) is a novel, potent and selective inhibitor of poly (ADP-ribose) polymerase-1 (PARP1) with potential anticancer activity.

Atamparib (RBN-2397; RBN2397) is a first-in-class, potent, orally bioactive and NAD+ competitive inhibitor of PARP7 (IC50<3 nM) with antitumor and immunomodulatory effects.

Veliparib dihydrochloride (also known as ABT888 dihydrochloride; ABT-888 dihydrochloride) is a novel and potent inhibitor of PARP1 and PARP2 [Poly (ADP-Ribose) Polymerase] with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively.

G007-LK is a novel, potent and specific tankyrase (TNKS) 1/2 inhibitor with potential anticancer activity.

Talazoparib racemic (formerly known as BMN 673 and MDV 3800), the racemic mixture of talazoparib, is a potent PARP1/2 [poly(ADP-ribose) polymerase] inhibitor with favorable pharmacokinetic properties.